Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction
Chris J. Kapelios, Bahira Shahim, Lars H. Lund, Gianluigi Savarese
Abstract
Heart failure (HF) is a global pandemic affecting 64 million people worldwide. HF with preserved ejection fraction (HFpEF) has traditionally received less attention than its main counterpart, HF with reduced ejection fraction (HFrEF). The incidence and prevalence of HFpEF show geographic variation and are increasing over time, soon expected to surpass those of HFrEF. Morbidity and mortality rates of HFpEF are considerable, albeit lower than those of HFrEF. This review focuses on the burden of HFpEF, providing contemporary data on epidemiology, clinical characteristics and comorbidities, cause-specific outcomes, costs and pharmacotherapy.
Topics & Concepts
Ejection fractionHeart failureHeart failure with preserved ejection fractionEpidemiologyMedicineCardiologyInternal medicinePandemicCoronavirus disease 2019 (COVID-19)Incidence (geometry)PharmacotherapyIntensive care medicineDiseasePhysicsOpticsInfectious disease (medical specialty)Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsDiabetes Treatment and Management